These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33848263)

  • 1. MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease.
    Bao J; Lu Y; She Q; Dou W; Tang R; Xu X; Zhang M; Zhu L; Zhou Q; Li H; Zhou G; Yang Z; Shi S; Liu Z; Zheng C
    JCI Insight; 2021 May; 6(10):. PubMed ID: 33848263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15.
    Patel SK; Velkoska E; Gayed D; Ramchand J; Lesmana J; Burrell LM
    BMC Nephrol; 2018 Jul; 19(1):159. PubMed ID: 29970016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212.
    Sárközy M; Gáspár R; Zvara Á; Siska A; Kővári B; Szűcs G; Márványkövi F; Kovács MG; Diószegi P; Bodai L; Zsindely N; Pipicz M; Gömöri K; Kiss K; Bencsik P; Cserni G; Puskás LG; Földesi I; Thum T; Bátkai S; Csont T
    Sci Rep; 2019 Feb; 9(1):1302. PubMed ID: 30718600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
    Chuppa S; Liang M; Liu P; Liu Y; Casati MC; Cowley AW; Patullo L; Kriegel AJ
    Kidney Int; 2018 Feb; 93(2):375-389. PubMed ID: 28760335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity.
    Inoue K; Matsui I; Hamano T; Okuda K; Tsukamoto Y; Matsumoto A; Shimada K; Yasuda S; Katsuma Y; Takabatake Y; Tanaka M; Tanaka N; Mano T; Minamino T; Sakata Y; Isaka Y
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):381-397. PubMed ID: 33206298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.
    Yan L; Mathew L; Chellan B; Gardner B; Earley J; Puri TS; Hofmann Bowman MA
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1399-411. PubMed ID: 24855059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts.
    Curcio A; Torella D; Iaconetti C; Pasceri E; Sabatino J; Sorrentino S; Giampà S; Micieli M; Polimeni A; Henning BJ; Leone A; Catalucci D; Ellison GM; Condorelli G; Indolfi C
    PLoS One; 2013; 8(7):e70158. PubMed ID: 23922949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
    Burrell LM; Burchill L; Dean RG; Griggs K; Patel SK; Velkoska E
    Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
    Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
    J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic background influences cardiac phenotype in murine chronic kidney disease.
    Neuburg S; Dussold C; Gerber C; Wang X; Francis C; Qi L; David V; Wolf M; Martin A
    Nephrol Dial Transplant; 2018 Jul; 33(7):1129-1137. PubMed ID: 29309658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study.
    Bayauli MP; Lepira FB; Kayembe PK; M'buyamba-Kabangu JR
    Cardiovasc J Afr; 2012 Mar; 23(2):73-7. PubMed ID: 22447475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.